{
    "organizations": [],
    "uuid": "f79fc935e92c0042fe40344e0506d62e29ceed83",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-precipio-launches-unique-lung-canc/brief-precipio-launches-unique-lung-cancer-monitoring-test-for-therapy-resistance-idUSFWN1Q5164",
    "ord_in_thread": 0,
    "title": "BRIEF-Precipio Launches Unique Lung Cancer Monitoring Test For Therapy Resistance",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 15 (Reuters) - Precipio Inc:\n* PRECIPIO LAUNCHES UNIQUE LUNG CANCER MONITORING TEST FOR THERAPY RESISTANCE\n* PRECIPIO INC - LAUNCHES FIRST LUNG CANCER TREATMENT RESISTANCE PANEL SPECIFICALLY FOR CRITICAL MUTATIONS T790M AND C797S IN EGFR GENE\n* PRECIPIO INC - LUNG CANCER TREATMENT RESISTANCE PANEL IS BILLED AT BELOW $500 FOR BOTH T790M AND C797S MUTATIONS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-15T22:14:00.000+02:00",
    "crawled": "2018-02-16T16:39:58.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "precipio",
        "inc",
        "precipio",
        "launch",
        "unique",
        "lung",
        "cancer",
        "monitoring",
        "test",
        "therapy",
        "resistance",
        "precipio",
        "inc",
        "launch",
        "first",
        "lung",
        "cancer",
        "treatment",
        "resistance",
        "panel",
        "specifically",
        "critical",
        "mutation",
        "t790m",
        "c797s",
        "egfr",
        "gene",
        "precipio",
        "inc",
        "lung",
        "cancer",
        "treatment",
        "resistance",
        "panel",
        "billed",
        "t790m",
        "c797s",
        "mutation",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}